Opicinumab
Opicinumab
Opicinumab (pronunciation: oh-pi-sin-u-mab) is a monoclonal antibody that is currently being studied for its potential use in the treatment of multiple sclerosis (MS).
Etymology
The name "Opicinumab" is derived from the Latin word "Opicinus", which means "to see" or "to observe", and "mab", which is a common suffix for monoclonal antibodies.
Description
Opicinumab is a type of monoclonal antibody that is designed to target and bind to a specific protein found on the surface of cells. This protein, known as LINGO-1, is believed to inhibit the growth and repair of nerve fibers in the brain and spinal cord. By binding to LINGO-1, opicinumab may help to promote the repair of damaged nerve fibers and improve neurological function in individuals with MS.
Clinical Trials
Opicinumab has been evaluated in several clinical trials for its safety and efficacy in treating MS. The results of these trials have been mixed, with some studies showing a potential benefit and others showing no significant effect. Further research is needed to determine the role of opicinumab in the treatment of MS.
Related Terms
See Also
External links
- Medical encyclopedia article on Opicinumab
- Wikipedia's article - Opicinumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski